AUP

Aurinia PharmaceuticalsTSX:AUP Stock Report

Market Cap

CA$2.2b

7D

0%

1Y

-8.9%

Updated

24 Aug, 2021

Data

Company Financials +
AUP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AUP Overview

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China.

Aurinia Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aurinia Pharmaceuticals
Historical stock prices
Current Share PriceCA$16.76
52 Week HighCA$11.77
52 Week LowCA$26.00
Beta0.28
1 Month Change17.29%
3 Month Change-2.27%
1 Year Change-8.86%
3 Year Change125.88%
5 Year Change554.69%
Change since IPO-69.53%

Recent News & Updates

Jun 25
Companies Like Aurinia Pharmaceuticals (TSE:AUP) Can Afford To Invest In Growth

Companies Like Aurinia Pharmaceuticals (TSE:AUP) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

AUPCA BiotechsCA Market
7D0%1.7%-0.6%
1Y-8.9%-1.4%28.9%

Return vs Industry: AUP underperformed the Canadian Biotechnology industry which returned -1.4% over the past year.

Return vs Market: AUP underperformed the Canadian Market which returned 25.7% over the past year.

Price Volatility

Is AUP's price volatile compared to industry and market?
AUP volatility
AUP Beta0.28
Industry Beta1.3
Market Beta1

Stable Share Price: AUP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: AUP's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a294Peter Greenleafhttps://www.auriniapharma.com

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia Pharmaceuticals Fundamentals Summary

How do Aurinia Pharmaceuticals's earnings and revenue compare to its market cap?
AUP fundamental statistics
Market CapUS$1.71b
Earnings (TTM)-US$147.59m
Revenue (TTM)US$57.59m

29.1x

P/S Ratio

-11.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AUP income statement (TTM)
RevenueUS$57.59m
Cost of RevenueUS$45.70m
Gross ProfitUS$11.90m
ExpensesUS$159.49m
Earnings-US$147.59m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.17
Gross Margin20.66%
Net Profit Margin-256.27%
Debt/Equity Ratio0%

How did AUP perform over the long term?

See historical performance and comparison

Valuation

Is Aurinia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AUP (CA$16.76) is trading below our estimate of fair value (CA$173.61)

Significantly Below Fair Value: AUP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AUP is unprofitable, so we can't compare its PE Ratio to the North American Biotechnology industry average.

PE vs Market: AUP is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AUP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AUP is overvalued based on its PB Ratio (5.1x) compared to the CA Biotechnology industry average (3.5x).


Future Growth

How is Aurinia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

74.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: AUP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AUP's is expected to become profitable in the next 3 years.

Revenue vs Market: AUP's revenue (53.8% per year) is forecast to grow faster than the Canadian market (4.8% per year).

High Growth Revenue: AUP's revenue (53.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AUP's Return on Equity is forecast to be high in 3 years time (31%)


Past Performance

How has Aurinia Pharmaceuticals performed over the past 5 years?

-27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AUP is currently unprofitable.

Growing Profit Margin: AUP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AUP is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.

Accelerating Growth: Unable to compare AUP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechnology industry (0.1%).


Return on Equity

High ROE: AUP has a negative Return on Equity (-44.42%), as it is currently unprofitable.


Financial Health

How is Aurinia Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AUP's short term assets ($349.7M) exceed its short term liabilities ($29.3M).

Long Term Liabilities: AUP's short term assets ($349.7M) exceed its long term liabilities ($24.7M).


Debt to Equity History and Analysis

Debt Level: AUP is debt free.

Reducing Debt: AUP has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AUP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AUP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AUP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AUP's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Peter Greenleaf (51 yo)

2.33yrs

Tenure

US$10,678,868

Compensation

Mr. Peter S. Greenleaf, M.B.A., has been President, Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019. Mr. Greenleaf has been a Director at Antares Pharma, Inc. sinc...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD10.68M) is above average for companies of similar size in the Canadian market ($USD2.04M).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AUP's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: AUP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AUP insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Aurinia Pharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Aurinia Pharmaceuticals Inc.
  • Ticker: AUP
  • Exchange: TSX
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$2.152b
  • Shares outstanding: 128.40m
  • Website: https://www.auriniapharma.com

Number of Employees


Location

  • Aurinia Pharmaceuticals Inc.
  • 4464 Markham Street
  • Suite 1203
  • Victoria
  • British Columbia
  • V8Z 7X8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/24 22:10
End of Day Share Price2021/07/30 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.